A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Wang, Yu; Wang, Xiaohua; Yu, Yixin; Yuan, Liyan; Yu, Xinmin; Yang, Bin

doi:10.1111/dth.15081

Cited by 7 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various real-world factors may affect treatment patterns, including economic burden, disease remission, and ineffectiveness. 26 In the present study, 40.0% of the patients achieved PASI 75 at week 4, whereas 92.1% achieved PASI 75 at week 12. This supports the findings of previous studies in China [25][26][27][28][29] and provides strong evidence for the effectiveness of secukinumab in a larger cohort covering a wider geographic area.…”

Section: Discussionsupporting

confidence: 43%

“…Therefore, it is highly effective in improving PASI, IGA, BSA, and DLQI among patients with moderate‐to‐severe plaque psoriasis in Chinese real‐world settings, with a rapid response at 12 weeks after initiation and sustainable effects with continuous treatment for 24 weeks. Various real‐world factors may affect treatment patterns, including economic burden, disease remission, and ineffectiveness 26 …”

Section: Discussionmentioning

confidence: 99%

“…Secukinumab, an IL‐17A inhibitor, 18 is recommended in multiple guidelines, 18–21 including the 2021 Chinese Guidelines 19 for adults with moderate‐to‐severe plaque psoriasis. Secukinumab effectively treated psoriasis in clinical trials 22–24 and real‐world studies in China 25–29 …”

Section: Introductionmentioning

confidence: 99%

“…Secukinumab effectively treated psoriasis in clinical trials [22][23][24] and real-world studies in China. [25][26][27][28][29] Previous real-world studies in China [25][26][27][28][29] on secukinumab's effectiveness have consistently reported excellent treatment responses at week 12 since initiation (~90% of patients achieved a ≥75% reduction in Psoriasis Area and Severity Index [PASI] scores). In China, data on secukinumab's optimal treatment patterns, effectiveness, and safety in real-world settings are lacking.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

Ding,

Li,

Guan

et al. 2023

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

Secukinumab is effective in treating patients with moderate‐to‐severe plaque psoriasis. However, most studies assessing its effectiveness in routine clinical settings in China are mostly single‐center studies with a limited sample size. The objective of this study was to assess secukinumab's efficacy, treatment patterns, and characteristics in patients with moderate‐to‐severe plaque psoriasis. This 24‐week, multicenter (n = 5) retrospective study analyzed the data of Chinese adult patients with moderate‐to‐severe plaque psoriasis who initiated secukinumab treatment between May 2019 and March 2020. The Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator's Global Assessment Modified 2011 (IGA mod 2011), and Dermatology Life Quality Index (DLQI) were assessed. Dermatologists documented the treatment dosage and modification reasons. Of the 244 secukinumab‐naïve patients, most were men (73.4%, 179/244) and weighed 60–90 kg (72.8%, 177/243). The mean (SD) age at secukinumab initiation was 38.1 (11.6) years, and the disease duration was 13.5 (7.9) years. Most patients (97.1%, 237/244) received secukinumab 300 mg. At weeks 4, 12, 16, and 24, the proportion of patients achieving PASI 75 (≥75% reduction from baseline) was 40.0%, 92.1%, 88.4%, and 88.9%, respectively; PASI 90 was 15.0%, 73.7%, 81.4%, and 68.3%, respectively; and PASI 100 was 8.7%, 40.8%, 58.1%, and 41.3%, respectively. During the same periods, BSA and IGA mod 2011 showed similar improvement trends. An increasing proportion of patients achieved DLQI of 0–1 (21.6%, 65.7%, 75.0%, and 80.3%, respectively). Treatment modification was highest at week 12. The average interval between two administrations after week 4 was 62.95 days. Secukinumab was highly effective in improving the PASI, IGA, BSA, and DLQI in Chinese patients with moderate‐to‐severe plaque psoriasis throughout the first 24 weeks. The treatment pattern for Chinese patients differs from that in the clinical guidelines.

show abstract

Section: Discussionsupporting

confidence: 43%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

Ding,

Li,

Guan

et al. 2023

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…With a better understanding of pathogenesis, dermatologists began to create new pathogenesis-based therapies, especially various biologics. Over the past two decades, a variety of biologics have been proved to be safe and effective in the treatment of psoriasis, especially in moderate-to-severe psoriasis ( 13 , 59 , 60 ). Biologics are recommended by the American Academy of Dermatology-National Psoriasis Foundation guidelines as a first-line treatment option for moderate-to-severe plaque psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Stigmatization in Patients With Psoriasis: A Mini Review

et al. 2021

View full text Add to dashboard Cite

Psoriasis is a chronic and recurrent immune-related skin disease that often causes disfigurement and disability. Due to the visibility of lesions in patients and inadequate understanding of dermatology knowledge in the general public, patients with psoriasis often suffer from stigma in their daily lives, which has adverse effects on their mental health, quality of life, and therapeutic responses. This review summarized the frequently used questionnaires and scales to evaluate stigmatization in patients with psoriasis, and recent advances on this topic. Feelings of Stigmatization Questionnaire, Questionnaire on Experience with Skin Complaints, and 6-item Stigmatization Scale have been commonly used. The relationship between sociodemographic characteristics, disease-related variables, psychiatric disorders, quality of life, and stigmatization in patients with psoriasis has been thoroughly investigated with these questionnaires. Managing the stigmatization in patients with psoriasis needs cooperation among policymakers, dermatologists, psychologists, psychiatrists, researchers, and patients. Further studies can concentrate more on these existing topics, as well as other topics, including predictors of perceived stigmatization, stigmatization from non-patient groups, influence of biologics on stigmatization, and methods of coping with stigmatization.

show abstract

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Thomas,

Barenbrug,

Hannink

et al. 2024

Drugs

View full text Add to dashboard Cite

Background and Objective The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking. Therefore, our objective was to assess the drug survival of IL-17 and IL-23 inhibitors for psoriasis. Methods A search of PubMed, Embase, Cochrane Library and Web of Science was conducted (last search 27 December, 2023). Inclusion criteria were (1) cohort study; (2) patients aged ≥ 18 years with plaque psoriasis; and (3) evaluation of drug survival of at least one of the IL-17 and IL-23 inhibitors. Exclusion criteria were: primary focus on patients with psoriatic arthritis, fewer than ten study subjects and another language than English. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed. Survival probabilities at monthly intervals were extracted from Kaplan–Meier curves using a semi-automated tool. Data were pooled using a non-parametric random-effects model to retrieve distribution-free summary survival curves. Summary drug survival curves were constructed per biologic for different discontinuation reasons: overall, ineffectiveness and adverse events, and split for the effect modifier biologic naivety. Results were analysed separately for registry/electronic health record data and for pharmacy/claims data. Results A total of 69 studies aggregating drug survival outcomes of 48,704 patients on secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab were included. Summary drug survival estimates of registry/electronic health record studies for overall, ineffectiveness and adverse event related drug survival were high (all point estimates ≥ 0.8 at year 1) for included biologics, with highest estimates for guselkumab and risankizumab. All estimates for drug survival were higher in biologic naive than in experienced patients. Estimates of pharmacy/claims databases were substantially lower than estimates from the primary analyses based on registry/electronic health record data. Conclusions This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-024-02028-1.

show abstract

A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China

Cited by 7 publications

References 15 publications

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study

Stigmatization in Patients With Psoriasis: A Mini Review

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About